Celemics KRX:331920KOSDAQ

셀레믹스 · Korean news coverage and regulatory filings, organized.

Articles, 24h1
Articles, 7 days1
DART filings, 7 days0
Articles tracked1since Sep 11

In Q2 2026, Celemics reported revenue of ₩1.4bn, up 22.4% year on year, and an operating loss of ₩924m. Celemics (셀레믹스) appeared in 1 Korean news article and 0 DART filings over the past seven days. Coverage peaked on Oct 30 with 1 article. The most common catalyst was contracts & orders (1).

Filing signals 4 quarters of losses Screener

Celemics quarterly results consolidated, KRW

QuarterRevenueYoYOperating profitNet income
Q2 2026₩1.4bn+22.4%−₩924m
margin −67.2%
−₩5.2bn
Q1 2026₩923m-46.4%−₩1.4bn
margin −154.4%
−₩6.0bn
Q4 2025 derived₩1.7bn-18.0%−₩456m
margin −27.5%
−₩814m
Q3 2025₩1.3bn-7.2%−₩1.1bn
margin −85.4%
−₩1.5bn
Q2 2025₩1.1bn-24.8%−₩1.3bn
margin −119.5%
−₩2.9bn
Q1 2025₩1.7bn-6.4%−₩447m
margin −25.9%
−₩2.2bn
Q4 2024 derived₩2.0bn+53.7%−₩141m
margin −7.0%
−₩9.3bn
Q3 2024₩1.4bn-4.9%−₩483m
margin −35.6%
₩9.6bn

Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.

Celemics top stories 2 weeks, by number of outlets

  1. 1
    셀레믹스, 식약처 니트로사민 유전독성 평가 연구 수주…NGS 적용 확대
    1 outlets · 1 articlesFirst report Oct 30 11:40 바이오타임즈Order / supply contract

Latest Celemics news Korean headlines